Foretinib (GSK1363089): ATP-Competitive VEGFR and HGFR Inhibitor for Cancer Research

Executive Summary: Foretinib (GSK1363089), distributed by APExBIO, is a nanomolar-potency, ATP-competitive multikinase inhibitor that targets VEGFRs and HGFR/Met, with IC₅₀ values from 0.4–9.6 nmol/L under in vitro conditions (Schwartz 2022). Foretinib inhibits tumor cell growth, migration, and invasion in models such as murine B16F10 melanoma and PC-3 prostate cancer cells (APExBIO product page). In vivo, oral dosing at 30 mg/kg reduces metastatic nodules in ovarian cancer xenografts. Mechanistically, Foretinib blocks HGF-induced motility and induces G2/M cell cycle arrest in multiple cancer lines. Its solubility profile (≥31.65 mg/mL in DMSO, insoluble in water/ethanol) requires careful experimental handling.

Biological Rationale

Receptor tyrosine kinases (RTKs) such as VEGFRs (vascular endothelial growth factor receptors) and HGFR (hepatocyte growth factor receptor/Met) regulate angiogenesis, cell proliferation, and metastasis in cancer (Schwartz 2022). Overexpression or constitutive activation of these kinases promotes tumor growth and dissemination. Multikinase inhibitors like Foretinib enable simultaneous blockade of redundant oncogenic pathways, offering improved efficacy compared to single-target approaches. Foretinib targets Met, Ron, KDR (VEGFR2), Flt-1, Flt-4 (VEGFR3), KIT, Flt-3, PDGFRα/β, and Tie-2. Nanomolar inhibition of these kinases disrupts key signaling networks responsible for tumor cell survival and motility (related article). While prior reviews often focus on individual kinase pathways, this article extends the discussion by integrating in vitro and in vivo evidence for Foretinib's systems-level effects on cancer biology.

Mechanism of Action of Foretinib (GSK1363089)

Foretinib is a small-molecule, ATP-competitive inhibitor. It binds within the ATP-binding pocket of multiple RTKs, preventing autophosphorylation and downstream signaling. Key targets include:

• Met (HGFR): Primary receptor for hepatocyte growth factor; Foretinib blocks HGF-induced cell motility and proliferation (Schwartz 2022).
• VEGFR2 (KDR), VEGFR1 (Flt-1), VEGFR3 (Flt-4): Central to vascular endothelial signaling; inhibition suppresses angiogenesis.
• PDGFRα/β, KIT, Flt-3, Tie-2, Ron: Modulate tumor stroma, hematopoietic, and metastatic processes.

Foretinib’s IC₅₀ values for kinase inhibition range from 0.4 to 9.6 nmol/L in biochemical assays. In cellular models, the IC₅₀ for MET phosphorylation is 21–23 nmol/L. This multi-target approach disrupts both tumor cell-autonomous and microenvironmental signaling. Foretinib also induces G2/M cell cycle arrest, reducing proliferation rates across diverse cancer cell lines (mechanistic context). This article clarifies the translational impact of these mechanisms, contrasting with prior focus on biochemical assays alone.

Evidence & Benchmarks

• Foretinib inhibits Met, Ron, KDR, Flt-1, Flt-4, KIT, Flt-3, PDGFRα/β, and Tie-2 with IC₅₀ values spanning 0.4–9.6 nmol/L (in vitro kinase assays) (DOI).
• In PC-3 prostate, B16F10 melanoma, A549 lung, and HT29 colon cancer cells, Foretinib's IC₅₀ for MET inhibition is 21–23 nmol/L (cellular assays) (DOI).
• Foretinib suppresses tumor cell migration and invasion in HGF-stimulated assays, with significant inhibition at nanomolar concentrations (migration/invasion assays) (DOI).
• In vivo, oral Foretinib (30 mg/kg) reduces both the number of metastatic nodules and tumor weight in ovarian cancer xenograft models (mouse, oral gavage, daily dosing) (DOI).
• Foretinib induces G2/M cell cycle arrest, as evidenced by flow cytometry in multiple cell lines (in vitro, 24–48 h exposure) (DOI).

Applications, Limits & Misconceptions

Foretinib is intended for preclinical research only. Its primary applications include:

• Dissecting VEGF and HGF/Met signaling in cancer cell lines and xenograft models.
• Evaluating tumor cell growth, migration, invasion, and cell cycle progression in response to kinase inhibition.
• Screening for combinatorial effects with other pathway inhibitors.
• Modeling anti-angiogenic and anti-metastatic mechanisms.

Prior reviews (see this article) focus on biochemical profiling; this article updates integration with advanced cell-based and animal models, providing a more holistic evidence base.

Common Pitfalls or Misconceptions

• Foretinib is not intended for clinical or diagnostic use; it is strictly for research applications (see APExBIO terms).
• It is insoluble in water and ethanol; only DMSO (≥31.65 mg/mL) is recommended as a solvent.
• The compound is light- and temperature-sensitive: stock solutions should be stored at –20°C, protected from light, and used promptly to avoid degradation.
• Results obtained in cell-free kinase assays may not be directly extrapolatable to cellular or in vivo models due to pharmacokinetic and matrix effects.
• Foretinib’s broad kinase inhibition may affect non-tumor cell populations, requiring careful experimental controls and interpretation.

Workflow Integration & Parameters

To maximize reliability, Foretinib experiments should adhere to the following parameters:

• Stock solution preparation: Dissolve in DMSO at concentrations up to 31.65 mg/mL; avoid water or ethanol.
• Storage: Aliquot and store at –20°C, protected from light; minimize freeze-thaw cycles.
• Cellular assays: Use serum-containing media unless otherwise specified; typical exposure is 24–72 h for proliferation, migration, or cell cycle endpoints.
• In vivo dosing: Oral gavage at 30 mg/kg/day in xenograft models is empirically validated for anti-tumor efficacy.
• Controls: Include DMSO vehicle, untreated, and positive controls (e.g., known MET or VEGFR inhibitors) for benchmarking.
• For detailed troubleshooting and advanced experimental design, refer to the related article (Data-driven solutions)—this article extends those guidelines with additional in vivo evidence.

For product specifications and ordering, see the Foretinib (GSK1363089) product page (SKU A2974).

Conclusion & Outlook

Foretinib (GSK1363089) is a validated, potent ATP-competitive multikinase inhibitor for dissecting VEGFR and HGF/Met signaling in cancer research. Its nanomolar efficacy, spectrum of kinase targets, and robust in vitro/in vivo benchmarks make it a leading tool for oncology workflows. APExBIO supplies Foretinib for research use, supported by detailed protocols and batch quality control. Future developments may focus on combinatorial screening and resistance mechanisms, but current evidence supports Foretinib as a gold-standard reference for multikinase inhibition in cancer models (Schwartz 2022).